Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Azathioprine for ocular inflammatory diseases.

Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Suhler EB.

Am J Ophthalmol. 2009 Oct;148(4):500-509.e2. doi: 10.1016/j.ajo.2009.05.008. Epub 2009 Jul 1.

2.

Cyclophosphamide for ocular inflammatory diseases.

Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Foster CS.

Ophthalmology. 2010 Feb;117(2):356-65. doi: 10.1016/j.ophtha.2009.06.060. Epub 2009 Dec 6.

3.

Methotrexate for ocular inflammatory diseases.

Gangaputra S, Newcomb CW, Liesegang TL, Kaçmaz RO, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study.

Ophthalmology. 2009 Nov;116(11):2188-98.e1. doi: 10.1016/j.ophtha.2009.04.020. Epub 2009 Sep 12.

4.

Mycophenolate mofetil for ocular inflammation.

Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH.

Am J Ophthalmol. 2010 Mar;149(3):423-32.e1-2. doi: 10.1016/j.ajo.2009.09.026. Epub 2009 Dec 30.

5.

Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.

Galor A, Jabs DA, Leder HA, Kedhar SR, Dunn JP, Peters GB 3rd, Thorne JE.

Ophthalmology. 2008 Oct;115(10):1826-32. doi: 10.1016/j.ophtha.2008.04.026. Epub 2008 Jun 25.

PMID:
18579209
6.

Mycophenolate mofetil therapy for inflammatory eye disease.

Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP.

Ophthalmology. 2005 Aug;112(8):1472-7.

PMID:
16061096
7.

Cyclosporine for ocular inflammatory diseases.

Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Foster CS.

Ophthalmology. 2010 Mar;117(3):576-84. doi: 10.1016/j.ophtha.2009.08.010. Epub 2010 Jan 19.

8.

Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease.

Suelves AM, Arcinue CA, González-Martín JM, Kruh JN, Foster CS.

Ophthalmology. 2013 Jun;120(6):1201-9. doi: 10.1016/j.ophtha.2013.01.031. Epub 2013 Apr 16.

PMID:
23601800
9.

Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.

Thorne JE, Woreta FA, Jabs DA, Anhalt GJ.

Ophthalmology. 2008 Dec;115(12):2146-2152.e1. doi: 10.1016/j.ophtha.2008.08.002. Epub 2008 Oct 18.

PMID:
18930554
10.

Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.

Saw VP, Dart JK, Rauz S, Ramsay A, Bunce C, Xing W, Maddison PG, Phillips M.

Ophthalmology. 2008 Feb;115(2):253-261.e1. Epub 2007 Jul 26.

PMID:
17655931
11.

[Role of Azathioprine in steroid resistant non infectious ocular inflammatory diseases].

Cuchacovich M, Pacheco P, Díaz G, Rojas B, Stoppel J, Merino G, Verdaguer JI, Verdaguer J, Villarroel F.

Rev Med Chil. 2007 Jun;135(6):702-7. Epub 2007 Aug 22. Spanish.

12.

Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.

Sobrin L, Christen W, Foster CS.

Ophthalmology. 2008 Aug;115(8):1416-21, 1421.e1. doi: 10.1016/j.ophtha.2007.12.011. Epub 2008 Jan 25.

PMID:
18221998
13.

The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.

Miserocchi E, Baltatzis S, Roque MR, Ahmed AR, Foster CS.

Ophthalmology. 2002 Jan;109(1):111-8.

PMID:
11772589
14.

Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis.

Doycheva D, Zierhut M, Blumenstock G, Stuebiger N, Deuter C.

Graefes Arch Clin Exp Ophthalmol. 2011 Aug;249(8):1235-43. doi: 10.1007/s00417-011-1731-8. Epub 2011 Jul 1.

PMID:
21720813
15.

Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.

Hogan AC, McAvoy CE, Dick AD, Lee RW.

Ophthalmology. 2007 May;114(5):1000-6.

PMID:
17467532
16.

Treatment of ocular inflammatory disorders with daclizumab.

Papaliodis GN, Chu D, Foster CS.

Ophthalmology. 2003 Apr;110(4):786-9.

PMID:
12689903
17.

Mycophenolate mofetil for the treatment of uveitis.

Teoh SC, Hogan AC, Dick AD, Lee RW.

Am J Ophthalmol. 2008 Nov;146(5):752-60, 760.e1-3. doi: 10.1016/j.ajo.2008.03.004. Epub 2008 May 2.

PMID:
18455143
18.

Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.

Yates WB, Vajdic CM, Na R, McCluskey PJ, Wakefield D.

Ophthalmology. 2015 Feb;122(2):265-73. doi: 10.1016/j.ophtha.2014.08.024. Epub 2014 Oct 11.

PMID:
25312044
19.

Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome.

Kiss S, Letko E, Qamruddin S, Baltatzis S, Foster CS.

Ophthalmology. 2003 Sep;110(9):1764-9.

PMID:
13129875
20.

Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases.

Udoetuk JD, Dai Y, Ying GS, Daniel E, Gangaputra S, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group.

Ophthalmology. 2012 Aug;119(8):1569-74. doi: 10.1016/j.ophtha.2012.01.043. Epub 2012 Apr 6.

Items per page

Supplemental Content

Write to the Help Desk